Massive malawi trial aims to shield kids from typhoid
NCT ID NCT03299426
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This large phase 3 trial is testing a typhoid conjugate vaccine (Vi-TCV) in 30,000 healthy children aged 9 months to 12 years in Malawi. Half get the typhoid vaccine, half get a meningitis vaccine for comparison. The goal is to see if the typhoid vaccine prevents blood-confirmed typhoid fever and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Typhoid conjugate vaccine (Vi-TCV)
- What this could lead to
- If it works, this vaccine could protect children in typhoid-prone areas from a serious bacterial infection, reducing illness and deaths.
- What could go wrong
- This is a large trial, but results may not apply to all regions. The vaccine may cause side effects like pain or fever, and its long-term protection is still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPHOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Malawi Liverpool Wellcome Trust Clinical Research Programme, Queen Elizabeth Central Hospital College of Medicine
Blantyre, P.O. Box 30096, Malawi
More trials for these conditions
Other studies related to the condition(s) this trial covers.